THU0115 Importance of Both Disease Activity at 12 Weeks and Clinical Response up to 12 Weeks to Predict Achievement of Low Disease Activity at 52 Weeks During Abatacept Treatment in Biologics-Switching Patients with Rheumatoid Arthritis: A Multicenter Observational Cohort Study in Japan

BackgroundAccording to Treat to target strategy, we have to consider changing the treatment in 3-6 months. Clinical course of RA treatment should be important to predict further outcome and to decide the therapy management in clinical practice.ObjectivesWe aimed to assess the efficacy of abatacept (ABT) in rheumatoid arthritis (RA) patients in switching and identify predictive factors at baseline for low disease activity (LDA) or remission using data from a multicenter registry, Tsurumai Biologics Communication Registry (TBCR).MethodsFrom 2,771 RA patients registered until 2013, 225 patients with moderate or high disease activity received ABT were selected [switching for biologics failure; n=100 and naive; n=125]. We compared clinical course and baseline characteristics between biologics-naïve and switching patients who achieved LDA. Predictive factors for LDA achievement were determined by multivariate logistic regression analysis in each group. The best cut-off of DAS28-CRP until 24 weeks for LDA achievement at 52 weeks was determined using Receiver operating characteristics (ROC) curve.ResultsBaseline characteristics of study population (n=225) was mean age; 64.7yeras, disease duration; 11.5 years and baseline DAS28-CRP; 4.70, concomitant MTX use; 49.3% (mean dose; 7.3 mg/week). The biologics-naïve patients could achieve LDA at 52 weeks significantly more than in biologics-switching patients (56.0% vs 23.0%, p